Coherus Oncology, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Coherus Oncology, Inc. (CHRS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $1.96 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$8.65M.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $62.20M.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$51.57M, a 224.70% decline year-over-year.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$23.00K, a 100.11% decline year-over-year.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $1.96M.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$33.28M, a 524.80% decline from fiscal 2015.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $7.83M, a 92.93% decline from fiscal 2014.
- Coherus Oncology, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $110.84M, a 343.25% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $53.56M derived: sum of 2 quarters · filed 2018-03-08 | $1.99M derived: sum of 3 quarters · filed 2018-03-08 | $1.96M 10-K · filed 2018-03-08 |
| 2017-09-30 | $62.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $10.63M derived: sum of 2 quarters · filed 2017-11-06 | $10.61M 10-Q · filed 2017-11-06 | -$24.12M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | -$51.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$51.59M 10-Q · filed 2017-08-07 | -$86.33M derived: sum of 3 quarters · filed 2018-03-08 | -$147.56M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | -$23.00K 10-Q · filed 2017-05-08 | -$34.75M derived: sum of 2 quarters · filed 2018-03-08 | -$95.99M derived: sum of 3 quarters · filed 2018-03-08 | -$54.63M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | -$34.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$95.97M derived: sum of 2 quarters · filed 2018-03-08 | -$54.61M derived: sum of 3 quarters · filed 2018-03-08 | -$33.28M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$61.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | -$19.88M derived: sum of 2 quarters · filed 2017-11-06 | $1.45M 10-Q · filed 2017-11-06 | $5.99M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $41.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $62.69M 10-Q · filed 2017-08-07 | $67.22M derived: sum of 3 quarters · filed 2018-03-08 | $14.83M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $21.33M 10-Q · filed 2017-05-08 | $25.87M derived: sum of 2 quarters · filed 2018-03-08 | -$26.53M derived: sum of 3 quarters · filed 2018-03-08 | $64.42M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$47.86M derived: sum of 2 quarters · filed 2018-03-08 | $43.09M derived: sum of 3 quarters · filed 2018-03-08 | $7.83M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$52.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $38.55M derived: sum of 2 quarters · filed 2016-11-09 | $3.30M 10-Q · filed 2016-11-09 | $52.82M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $90.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $55.70M 10-Q · filed 2016-08-09 | $105.21M derived: sum of 3 quarters · filed 2017-03-14 | $97.22M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | -$35.26M 10-Q · filed 2016-05-09 | $14.26M derived: sum of 2 quarters · filed 2017-03-14 | $6.27M derived: sum of 3 quarters · filed 2017-03-14 | $58.82M derived: sum of 4 quarters · filed 2017-03-14 |
| 2014-12-31 | $49.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $41.52M derived: sum of 2 quarters · filed 2017-03-14 | $94.08M derived: sum of 3 quarters · filed 2017-03-14 | $110.84M 10-K · filed 2017-03-14 |
| 2014-09-30 | -$7.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $44.56M derived: sum of 2 quarters · filed 2015-11-10 | $61.32M 10-Q · filed 2015-11-10 | $66.16M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $52.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $69.31M 10-Q · filed 2015-08-10 | $74.15M derived: sum of 3 quarters · filed 2016-02-29 | |
| 2014-03-31 | $16.76M 10-Q · filed 2015-05-11 | $21.60M derived: sum of 2 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $25.01M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $20.17M 10-Q · filed 2014-12-15 | |||
| 2012-12-31 | $6.86M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |